Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women: A randomized clinical trial

JAMA Psychiatry

Volumn 73, Issue 9, 2016, Pages 947-954

  Kulkarni, Jayashri ^a   Gavrilidis, Emorfia ^a   Gwini, Stella M ^b   Worsley, Roisin ^a   Grigg, Jasmin ^a   Warren, Annabelle ^a   Gurvich, Caroline ^a   Gilbert, Heather ^a   Berk, Michael ^c   Davis, Susan R ^b  

^a Australia   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROGESTERONE; PROLACTIN; RALOXIFENE; NEUROLEPTIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ANDROGEN BLOOD LEVEL; ARTICLE; CLINICAL OUTCOME; COGNITION; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD CHANGE; ONSET AGE; OUTCOME ASSESSMENT; PARALLEL DESIGN; POSITIVE AND NEGATIVE SYNDROME SCALE; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG RESISTANCE; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOTIC DISORDERS;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RALOXIFENE HYDROCHLORIDE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84996605811     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2016.1383     Document Type: Article

References (70)

1. Freedman R. Schizophrenia. N Engl J Med. 2003; 349(48):1738-1749.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
3. Strittmatter SM. Overcoming drug development bottlenecks with repurposing: old drugs learn new tricks. Nat Med. 2014;20(6):590-591.
4. Berk M, Nierenberg AA. Three paths to drug discovery in psychiatry. Am J Psychiatry. 2015;172 (5):412-414.
5. Bumb JM, Enning F, Leweke FM. Drug repurposing and emerging adjunctive treatments for schizophrenia. Expert Opin Pharmacother. 2015; 16(7):1049-1067.
6. Riecher-Rössler A, Häfner H. Schizophrenia and oestrogens: is there an association? Eur Arch Psychiatry Clin Neurosci. 1993;242(6):323-328.
7. Seeman MV. The role of estrogen in schizophrenia. J Psychiatry Neurosci. 1996;21(2): 123-127.
8. Bethea CL, Mirkes SJ, Shively CA, Adams MR. Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques. Biol Psychiatry. 2000;47(6):562-576.
9. Fink G, Sumner BE,McQueen JK, Wilson H, Rosie R. Sex steroid control of mood, mental state and memory. Clin Exp Pharmacol Physiol. 1998;25 (10):764-775.
10. Fink G, Sumner BE, Rosie R, Grace O, Quinn JP. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol. 1996;16(3):325-344.
11. Häfner H, Behrens S, De Vry J, Gattaz WF. An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia. Psychiatry Res. 1991; 38(2):125-134.
12. Häfner H, Behrens S, De Vry J, Gattaz WF. Oestradiol enhances the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission: evidence from an epidemiological study and from animal experiments. Eur Arch Psychiatry Clin Neurosci. 1991;241(1):65-68.
13. Hiroi R, McDevitt RA, Neumaier JF. Estrogen selectively increases tryptophan hydroxylase-2 mRNA expression in distinct subregions of rat midbrain raphe nucleus: association between gene expression and anxiety behavior in the open field. Biol Psychiatry. 2006;60(3):288-295.
14. Vasudevan N, Pfaff DW. Non-genomic actions of estrogens and their interaction with genomic actions in the brain. Front Neuroendocrinol. 2008; 29(2):238-257.
15. Khan MM,Wakade C, de Sevilla L, Brann DW. Selective estrogen receptor modulators (SERMs) enhance neurogenesis and spine density following focal cerebral ischemia. J Steroid Biochem Mol Biol. 2015;146:38-47.
16. Sánchez MG, MorissetteM, Di Paolo T. Oestradiol modulation of serotonin reuptake transporter and serotonin metabolism in the brain of monkeys. J Neuroendocrinol. 2013;25(6):560-569.
17. Meitzen J, Mermelstein PG. Estrogen receptors stimulate brain region specific metabotropic glutamate receptors to rapidly initiate signal transduction pathways. J Chem Neuroanat. 2011;42 (4):236-241.
18. Sribnick EA, Wingrave JM, Matzelle DD, Wilford GG, Ray SK, Banik NL. Estrogen attenuated markers of inflammation and decreased lesion volume in acute spinal cord injury in rats. J Neurosci Res. 2005;82(2):283-293.
19. Pasqualini C, Olivier V, Guibert B, Frain O, Leviel V. Acute stimulatory effect of estradiol on striatal dopamine synthesis. J Neurochem. 1995;65(4): 1651-1657.
20. Becker JB. Oestrogen effects on dopaminergic function in striatum. Novartis Found Symp. 2000; 230:134-145.
21. Xiao L, Becker JB. Quantitative microdialysis determination of extracellular striatal dopamine concentration in male and female rats: effects of estrous cycle and gonadectomy. Neurosci Lett. 1994;180(2):155-158.
22. Gogos A, van den Buuse M. Comparing the effects of 17β-oestradiol and the selective oestrogen receptor modulators, raloxifene and tamoxifen, on prepulse inhibition in female rats. Schizophr Res. 2015;168(3):634-639.
23. Jacobs EG, Holsen LM, Lancaster K, et al. 17β-Estradiol differentially regulates stress circuitry activity in healthy and depressed women. Neuropsychopharmacology. 2015;40(3):566-576.
24. Kulkarni J, Gavrilidis E,WangW, et al. Estradiol for treatment-resistant schizophrenia: A large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry. 2015;20(6): 695-702.
25. Kulkarni J, Riedel A, de Castella AR, et al. A clinical trial of adjunctive oestrogen treatment in women with schizophrenia. ArchWomens Ment Health. 2002;5(3):99-104.
26. Begemann MJ, Dekker CF, van Lunenburg M, Sommer IE. Estrogen augmentation in schizophrenia: A quantitative review of current evidence. Schizophr Res. 2012;141(2-3):179-184.
27. Akhondzadeh S, Nejatisafa AA, Amini H, et al. Adjunctive estrogen treatment in women with chronic schizophrenia: A double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27 (6):1007-1012.
28. Ghafari E, Fararouie M, Shirazi HG, Farhangfar A, Ghaderi F, Mohammadi A. Combination of estrogen and antipsychotics in the treatment ofwomen with chronic schizophrenia: A double-blind, randomized, placebo-controlled clinical trial. Clin Schizophr Relat Psychoses. 2013;6(4):172-176.
29. Kulkarni J, de Castella A, Fitzgerald PB, et al. Estrogen in severe mental illness: A potential new treatment approach. Arch Gen Psychiatry. 2008;65 (8):955-960.
30. Bergemann N, Mundt C, Parzer P, et al. Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study. Schizophr Res. 2005;74(2-3): 125-134.
31. Beral V; MillionWomen Study Collaborators. Breast cancer and hormone-replacement therapy in the MillionWomen Study. Lancet. 2003;362 (9382):419-427.
32. Beral V, Bull D, Reeves G; MillionWomen Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005;365(9470):1543-1551.
33. Kulkarni J, Gavrilidis E,Worsley R, Hayes E. Role of estrogen treatment in the management of schizophrenia. CNS Drugs. 2012;26(7):549-557.
34. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science. 2002;295 (5564):2465-2468.
35. Cyr M, Calon F, MorissetteM, Grandbois M, Di Paolo T, Callier S. Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS. Curr Pharm Des. 2000;6(12):1287-1312.
36. LandryM, Lévesque D, Di Paolo T. Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology. 2002;76(4):214-222.
37. Vogel VG, Costantino JP, Wickerham DL, et al; National Surgical Adjuvant Breast and Bowel Project. Update of the national surgical adjuvant breast and bowel project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila). 2010;3(6):696-706.
38. Wenger NK, Barrett-Connor E, Collins P, et al. Baseline characteristics of participants in the Raloxifene Use for the Heart (RUTH) trial. Am J Cardiol. 2002;90(11):1204-1210.
39. Barrett-Connor E, Mosca L, Collins P, et al; Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355 (2):125-137.
40. Ettinger B, Black DM, Mitlak BH, et al; Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282(7):637-645.
41. Usall J, Coromina M, Araya S, Ochoa S. Effect of raloxifene (a selective estrogen receptor modulator [SERM]) as coadjuvant to antidepressant treatment: A case report. Actas Esp Psiquiatr. 2011; 39(5):334-336.
42. Yang ZD, Yu J, Zhang Q. Effects of raloxifene on cognition, mental health, sleep and sexual function in menopausal women: A systematic review of randomized controlled trials. Maturitas. 2013;75(4): 341-348.
43. Kulkarni J, Gurvich C, Lee SJ, et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology. 2010;35(8):1142-1147.
44. Usall J, Huerta-Ramos E, Iniesta R, et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: A double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2011;72(11):1552-1557.
45. Dhandapani A, Narayanaswamy JC, Venkatasubramanian G. Adjuvant raloxifene treatment for negative symptoms of schizophrenia. Asian J Psychiatr. 2013;6(3):254-255.
46. Raveendranathan D, Shivakumar V, JayaramN, Rao NP, Venkatasubramanian G. Beneficial effects of add-on raloxifene in schizophrenia. ArchWomens Ment Health. 2012;15(2):147-148.
47. Tharoor H, Goyal A. Raloxifene trial in postmenopausal woman with treatment-resistant schizophrenia. ArchWomens Ment Health. 2015;18 (5):741-742.
48. Shivakumar V, Venkatasubramanian G. Successful use of adjuvant raloxifene treatment in clozapine-resistant schizophrenia. Indian J Psychiatry. 2012;54(4):394.
49. Rodante DE, Usall J. Raloxifene as adjuvant in the treatment of schizophrenia: A review of efficacy and safety issues. J Symptoms Signs. 2014;3(4): 229-237.
50. Weickert TW,Weinberg D, Lenroot R, et al. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry. 2015;20(6):685-694.
51. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
52. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision.Washington, DC: American Psychiatric Association; 2000.
53. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
54. SoulesMR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW) Park City, Utah, July, 2001. Menopause. 2001;8(6):402-407.
55. Microsoft Corporation. Microsoft Excel [computer program]. Redmond,WA: Microsoft Corp; 2015.
56. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
57. Suzuki T, Remington G, Mulsant BH, et al. Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation. Psychiatry Res. 2012;197(1-2):1-6.
58. Davidson J, Turnbull CD, Strickland R, Miller R, Graves K. The Montgomery-Asberg Depression Scale: reliability and validity. Acta Psychiatr Scand. 1986;73(5):544-548.
59. Randolph C. RBANS Repeatable Battery for the Assessment of Neuropsychological Status: Manual. New York, NY: NCS Pearson Inc; 1999.
60. Using the ASC program: A training guide. J Psychiatr Pract. 2001;7(1):64-68.
61. National Institute of Mental Health Psychopharmacology Research Branch. Abnormal InvoluntaryMovement Scale (AIMS). Psychopharmacol Bull. 1988;24(4):781-783.
62. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
63. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
64. STATA [computer program]. Release 13. College Station, TX: StataCorp LP; 1996-2015.
65. Leucht S, Kane JM, KisslingW, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005;79(2-3):231-238.
66. Huerta-Ramos E, Iniesta R, Ochoa S, et al. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: A double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2014;24(2):223-231.
67. Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D. Raloxifene and risk for stroke based on the Framingham stroke risk score. Am J Med. 2009;122(8):754-761.
68. Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women: ameta-analysis. Thromb Haemost. 2008;99(2):338-342.
69. Daumit GL, Clark JM, Steinwachs DM, Graham CM, Lehman A, Ford DE. Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness. J Nerv Ment Dis. 2003;191(12):799-805.
70. Hartz SM, Pato CN, Medeiros H, et al; Genomic Psychiatry Cohort Consortium. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry. 2014;71(3):248-254.